Skip to main content
SpringerLink
Log in

PPI Therapy and Albumin are Better Predictors of Recurrent Clostridium difficile Colitis than Choice of Antibiotics

  • Original Article
  • Published:
Journal of Gastrointestinal Surgery Aims and scope

Abstract

Background

Recurrent Clostridium difficile colitis (RCDC) is common, but data regarding recurrence rates and predisposing factors are sparse.

Methods

A retrospective case–control study was performed, identifying all inpatients and outpatients ≥18 years of age with C. difficile colitis (CDC) confirmed by a positive stool sample collected at our institution from January 2008 to August 2011. Factors associated with RCDC, the number of RCDC episodes, and the need for admission for RCDC were sought.

Results

A total of 739 patients (male, 47 %) were studied, of whom 527 (71 %) received inpatient treatment for their index episode of CDC. There was no difference (p = 0.53) between RCDC rates for inpatients (17.6 %) and outpatients (19.8 %). While severity score and albumin were associated with RCDC in our population, use of proton pump inhibitors (PPIs) correlated with decreased RCDC (p = 0.006) and decreased need for admission (p = 0.005). The addition of vancomycin to metronidazole therapy did not lower RCDC rates (p = 0.52) or decrease the need for admission (p = 0.78).

Conclusions

Hypoalbuminemia strongly correlated with higher recurrence rates, while PPI therapy actually reduced RCDC, representing previously underappreciated potential therapeutic targets for lowering CDC recurrence. The addition of vancomycin to metronidazole did not improve RCDC rates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bartlett JG. Antibiotic-associated diarrhea. Clin Infect Dis. 1992;15:573–581.

    Article  PubMed  CAS  Google Scholar 

  2. McDonald LC, Owings M, Jernigan JB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg Infect Dis. 2006;12:409–415.

    Article  PubMed  Google Scholar 

  3. Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, Roberts T, Croyle K, Krystofiak S, Patel-Brown S, Pasculle AW, Paterson DL, Saul M, Harrison LH. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. InfectControl Hosp Epidemiol. 2005;26(3):273–280.

    Article  Google Scholar 

  4. Rupnik M, Wilcox M, Gerding D. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol. 2009;7:526–536.

    Article  PubMed  CAS  Google Scholar 

  5. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis. 1997;24(3):324–333.

    Article  PubMed  CAS  Google Scholar 

  6. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol. 2000;38(6):2386–2388.

    PubMed  CAS  Google Scholar 

  7. McFarland L, Elmer G, Surawicz C. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97:1769–1775.

    Article  PubMed  CAS  Google Scholar 

  8. Gerding DN. Treatment of Clostridium difficile-associated diarrhea and colitis. Curr Top Microbiol Immunol. 2000;250:127–139.

    PubMed  CAS  Google Scholar 

  9. Arvand A, Moser V, Schwehn C, Bettge-Weller G, Hensgens MP, Kuijper EJ. High prevalence of Clostridium difficile colonization among nursing home residents in Hesse, Germany. PLoS One. 2012;7(1):e30183.

    Article  PubMed  CAS  Google Scholar 

  10. Burns DA, Heap JT, Minton NP. The diverse sporulation characteristics of Clostridium difficile clinical isolates are not associated with type. Anaerobe. 2010;16:618–622.

    Article  PubMed  CAS  Google Scholar 

  11. McDonald L, Kilgore G, Thompson A, Owens RC, Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353(23):2433–2441.

    Article  PubMed  CAS  Google Scholar 

  12. Weiss K. Clostridium difficile and fluoroquinolones: is there a link? Int J Antimicrob Agents. 2009;33:S1, S29-S32.

    Article  PubMed  CAS  Google Scholar 

  13. Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, Fone DL, Allison MC. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther. 2006;24(4):613–619.

    Article  PubMed  CAS  Google Scholar 

  14. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhoea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies. Can Med Assoc J. 2004;171(1):33–38.

    Article  Google Scholar 

  15. U. S. Food and Drug Administration. Accessed on April 30, 2012; http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm290838.htm

  16. Davies SM, Geppert J, McDonald KM, Romano PS, Shojania KG. AHRQ Technical Reviews, Report No. 01-0035.

  17. Averill RF, Goldfield NI, Muldoon J, Steinbeck BA, Grant TM. A closer look at all-patient refined DRG’s. J AHMA 2002;73(1):46–50.

    Google Scholar 

  18. Kim YG, Graham DY, Jang BI. Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case–control analysis matched by propensity score. J Clin Gastroenterol. 2012;46:397–400.

    Article  PubMed  CAS  Google Scholar 

  19. Shah S, Lewis A, Leopold D, Dunstan F, Woodhouse K. Gastric acid suppression does not promote clostridial diarrhea in the elderly. Q J Med. 2000;93(3):175–181.

    Article  CAS  Google Scholar 

  20. Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN. A case–control study of community-associated Clostridium difficile infection. J Antimicrob Chemother. 2008;62(2):388–396.

    Article  PubMed  CAS  Google Scholar 

  21. Khanna S, Pardi DS. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol. 2010;4:409–416.

    Article  PubMed  Google Scholar 

  22. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–455.

    Article  PubMed  Google Scholar 

  23. Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, Lee JT, Jr. Prospective randomized trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhea and colitis. Lancet. 1983;2(8348):1043–1046.

    Article  PubMed  CAS  Google Scholar 

  24. Wenisch C, Parshalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis. 1996;22(5):813–818.

    Article  PubMed  CAS  Google Scholar 

  25. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK. Fidoxamicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364(5):422–431.

    Article  PubMed  CAS  Google Scholar 

  26. Whitman CB, Czosnowski QA. Fidoxamicin for the treatment of Clostridium difficile infections. Ann Pharmacother. 2012;46:219–228.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Colon and Rectal Surgery, Department of Surgery, College of Medicine, The Pennsylvania State University, 500 University Drive, H137, Hershey, PA, 17033, USA

    Alizah Rotramel, Lisa S. Poritz, Evangelos Messaris & David B. Stewart

  2. Department of Public Health Sciences, College of Medicine, The Pennsylvania State University, Hershey, PA, 17033, USA

    Arthur Berg

Authors
  1. Alizah Rotramel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa S. Poritz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Evangelos Messaris
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arthur Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David B. Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David B. Stewart.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rotramel, A., Poritz, L.S., Messaris, E. et al. PPI Therapy and Albumin are Better Predictors of Recurrent Clostridium difficile Colitis than Choice of Antibiotics. J Gastrointest Surg 16, 2267–2273 (2012). https://doi.org/10.1007/s11605-012-2037-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-012-2037-9

Keywords

Search

Navigation